For decades, statins like Lipitor and Zocor have been the cornerstone of cholesterol management. But as experts note, they don’t work for everyone — and now, a new wave of advanced therapies is ...
A new gene therapy shows promise in controlling cholesterol by lowering bad LDL levels, potentially reducing the risk of ...
AUSTIN, Texas and TOKYO, Nov. 14, 2025 /PRNewswire/ -- According to DataM Intelligence, the Cardiovascular Biologics Market Size was valued at approximately USD 2.20 billion in 2024 and is projected ...
An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.
Researchers report early but encouraging results on an experimental gene-editing treatment for high cholesterol.
A statin isn’t the only answer anymore to lowering cholesterol. The lipid-reducing medicines, among the most widely prescribed drugs in the U.S., have been a mainstay of heart-disease prevention and ...
A report on gene-editing drugs renews debate around long-term statin use as Indian cardiologists caution that risk assessment ...
In a phase 1 trial, a gene-editing therapy that targets ANGPTL3 was associated with few serious adverse events and at higher ...
Data presented at this year’s American Heart Association Scientific Sessions in New Orleans underline rapid advancements in ...
MedPage Today on MSN
Gene Therapy Shows Promise for Cutting LDL in Half in Tough-to-Treat Dyslipidemia
NEW ORLEANS – A single injection of a gene-edited protein was deemed productive and safe in patients with dyslipidemia that ...
The approach is “very exciting,” but one expert says a lot more research is needed, especially around safety, before clinical ...
In patients with atherosclerosis and/or diabetes without a prior heart attack or stroke, evolocumab cut the risk for first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback